PRESS RELEASE

Q2 2026 — Press release

Q2 2026PDF · 14 pages235 KB
- 1 -
News Release
____________________________________________________________________________
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial
Results; Highlights Key Regulatory and Clinical Milestones Across Broad,
Diverse Pipeline
Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of
KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as
WINREVAIR
Financial Highlights
- 	Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX)
o 	KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.4 Billion (5% Growth; 4%
Growth ex-FX); Includes KEYTRUDA QLEX Sales of $463 Million
o 	WINREVAIR Sales Were $588 Million (75% Growth; 75% Growth ex-FX)
o 	Animal Health Sales Were $1.8 Billion (8% Growth; 5% Growth ex-FX)
- 	GAAP Loss per Share Was $0.54; Non-GAAP Loss per Share Was $0.13; GAAP and
Non-GAAP Loss per Share Include a Charge of $2.31 per Share for the Acquisition of
Terns
Pipeline & Portfolio Highlights
- 	Received U.S. FDA Approval for LIPFENDRA (enlicitide), the First and Only Once-
Daily Oral PCSK9 Inhibitor To Reduce LDL-C in Adults With Hypercholesterolemia
- 	Announced Positive Data From TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan
(sac-TMT) in Certain Patients With Advanced or Recurrent Endometrial Cancer
- 	Announced Positive Phase 3 Results From Once-Weekly Investigational Oral HIV
Treatment Regimen of Islatravir and Lenacapavir, in Collaboration With Gilead
Full-Year 2026 Financial Outlook
- 	Narrows and Raises Expected Worldwide Sales Range To Be Between $66.3 Billion and
$67.3 Billion
- 	Now Expects Non-GAAP EPS To Be Between $2.66 and $2.76; Outlook Includes
Charges of $2.43 per Share for the Acquisition of Terns, Comprised of a One-Time
Charge of $2.31 per Share as Well as Costs of Approximately $0.12 per Share To
Finance the Acquisition and Advance MK-4208 (Formerly TERN-701)
1 Available in some markets as KEYTRUDA SC.

-- 1 of 14 --

- 2 -
RAHWAY, N.J., Aug. 4, 2026 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as
MSD outside the United States and Canada, today announced financial results for the second
quarter of 2026.
“We continued to make substantial progress across our business this quarter, driven by
strong execution and growing contributions from new product launches,” said Robert M. Davis,
chairman and chief executive officer. “The FDA approval of LIPFENDRA is an exciting moment
for our company and for patients, marking the latest milestone in our nearly 70-year legacy in
cardiovascular disease. Together with key regulatory and clinical advances across oncology,
HIV and immunology, this achievement reflects the strength of our pipeline and portfolio
transformation as we bring forward the next wave of innovation. I am confident in the ongoing
execution of our strategy as we deliver for patients and further enhance our long-term growth
trajectory.”
Financial Summary
$ in millions, except EPS amounts
Second Quarter
2026 	2025 	Change
Change Ex-
Exchange
Sales 	$16,607 	$15,806 	5% 	4%
GAAP net (loss) income2 	(1,335) 	4,427 	N/M 	N/M
Non-GAAP net (loss) income that excludes certain
items2,3* 	(330) 	5,366 	N/M 	N/M
GAAP EPS 	(0.54) 	1.76 	N/M 	N/M
Non-GAAP EPS that excludes certain items3* 	(0.13) 	2.13 	N/M 	N/M
*Refer to table on page 7.
N/M - Not meaningful
For the second quarter of 2026, Generally Accepted Accounting Principles (GAAP) loss /
earnings per share (EPS) assuming dilution was a loss per share of $0.54 and non-GAAP loss
per share was $0.13. Both the GAAP and non-GAAP loss per share were due to a charge for
the acquisition of Terns Pharmaceuticals, Inc. (Terns) of $2.31 per share. Both GAAP and non-
GAAP EPS in the second quarter of 2025 include a charge of $0.07 per share for an upfront
payment related to a license agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd. (Hengrui
Pharma).
Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to
restructuring programs, as well as income and losses from investments in equity securities.
Non-GAAP EPS in the second quarter of 2025 also excludes tax benefits primarily resulting
from favorable audit reserve adjustments.
2 Net (loss) income attributable to the Company.
3 The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of
these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to this release.

-- 2 of 14 --

- 3 -
Year-to-date results can be found in the attached tables.
Second-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
Second Quarter
$ in millions 	2026 	2025 	Change
Change Ex-
Exchange 	Commentary
Total Sales 	$16,607 	$15,806 	5% 	4%
Pharmaceutical 	14,760 	14,050 	5% 	4%
Increase primarily driven by growth in
oncology as well as cardiometabolic and
respiratory, partially offset by a decline in
diabetes.
KEYTRUDA/
KEYTRUDA QLEX 	8,366 	7,956 	5% 	4%
Growth primarily driven by strong global
uptake in earlier-stage indications,
including triple-negative breast cancer
(TNBC), cervical cancer, head and neck
cancer and bladder cancer, as well as
higher global demand in metastatic
indications, including urothelial cancer.
Sales of KEYTRUDA QLEX were $463
million.
GARDASIL/GARDASIL 9 	1,169 	1,126 	4% 	3%
Increase primarily due to higher demand
in Asia Pacific and Europe, as well as
favorable timing of tenders in Europe,
partially offset by lower demand in
certain other international markets.
PROQUAD, M-M-R II and
VARIVAX 	592 	609 	-3% 	-3%
Decrease primarily reflects lower
demand in the U.S., partially offset by
higher net pricing in the U.S., higher
demand in Europe and favorable private-
sector purchasing patterns for M-M-R II
in the U.S.
WINREVAIR 	588 	336 	75% 	75%
Growth primarily reflects continued
uptake in the U.S. and early launch
uptake in certain international markets,
particularly in Japan and Europe.
BRIDION 	497 	461 	8% 	8%
Growth primarily due to higher demand
and net pricing in the U.S.
JANUVIA/JANUMET 	429 	623 	-31% 	-31%
Decline primarily due to lower demand
and net pricing in the U.S. due to
competition, as well as lower demand in
China and most other international
markets due to ongoing generic
competition.
Lynparza* 	365 	370 	-1% 	-2% 	Relatively flat compared with prior year.
PREVYMIS 	295 	228 	29% 	28%
Increase primarily due to higher demand
in the U.S. and certain European
markets, reflecting in part the launch of
new indications.
Lenvima* 	283 	265 	7% 	6%
Growth primarily due to higher demand
in the U.S., partially offset by lower net
pricing.

-- 3 of 14 --

- 4 -
WELIREG 	271 	162 	67% 	67%
Growth primarily driven by higher
demand in the U.S. and continued
launch uptake in several international
markets, particularly in Japan, as well as
favorable wholesaler purchasing patterns
in the U.S.
OHTUVAYRE 	204 	- 	- 	-
Product obtained as part of the
Company’s October 2025 acquisition of
Verona Pharma plc. Includes a benefit
from the timing of specialty pharmacy
purchases in the U.S.
CAPVAXIVE 	184 	129 	42% 	40%
Increase primarily driven by launch
uptake in several international markets,
particularly in Asia Pacific and Europe,
as well as in the U.S.
VAXNEUVANCE 	148 	229 	-35% 	-36%
Decline primarily due to favorable prior
period public-sector activity in the U.S.,
which increased sales in that period, as
well as lower demand in the U.S. and in
most international markets in the current
period due to competitive pressure.
LAGEVRIO 	5 	83 	-95% 	-95%
Decline largely due to lower demand in
Japan and the U.S.
Animal Health 	1,775 	1,646 	8% 	5%
Growth attributable to both Livestock and
Companion Animal product portfolios.
Livestock 	1,041 	961 	8% 	6%
Growth primarily driven by higher
demand for ruminant and poultry
products.
Companion Animal 	734 	685 	7% 	5%
Growth primarily due to new product
launches. Sales of BRAVECTO line of
products were $359 million and $335
million in the current and prior-year
quarters, respectively, which represents
an increase of 7%, or 4% excluding
impact of foreign exchange.
Other Revenues** 	72 	110 	-35% 	-34%
Decline primarily due to lower revenue
from third-party manufacturing
arrangements.
*Alliance revenue for this product represents the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.

-- 4 of 14 --

- 5 -
Second-Quarter Expense and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs4
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP3
Second Quarter 2026
Cost of sales 	$4,395 	$1,067 	$184 	$- 	$3,144
Selling, general and administrative 	2,904 	17 	- 	- 	2,887
Research and development 	9,741 	6 	(1) 	- 	9,736
Restructuring costs 	151 	- 	151 	- 	-
Other (income) expense, net 	99 	- 	- 	(191) 	290
Second Quarter 2025
Cost of sales 	$3,557 	$576 	$165 	$- 	$2,816
Selling, general and administrative 	2,649 	15 	1 	- 	2,633
Research and development 	4,048 	3 	53 	- 	3,992
Restructuring costs 	560 	- 	560 	- 	-
Other (income) expense, net 	(7) 	- 	- 	(61) 	54
GAAP Expense, EPS and Related Information
Gross margin was 73.5% for the second quarter of 2026 compared with 77.5% for the
second quarter of 2025. The decrease was primarily due to higher amortization of intangible
assets and inventory write-downs.
Selling, general and administrative (SG&A) expenses were $2.9 billion in the second
quarter of 2026, an increase of 10% compared with the second quarter of 2025. The increase
was primarily due to higher administrative costs (including investments in IT), as well as higher
promotional costs in support of product launches.
Research and development (R&D) expenses were $9.7 billion in the second quarter of
2026 compared with $4.0 billion in the second quarter of 2025. The increase was largely due to
a $5.7 billion charge for the acquisition of Terns and higher clinical development spending,
partially offset by a $200 million reduction in R&D expenses as part of a funding agreement with
Blackstone Life Sciences (Blackstone). R&D expenses in the second quarter of 2025 include a
$200 million charge for an upfront payment related to a license agreement with Hengrui
Pharma.
Other (income) expense, net, was $99 million of expense in the second quarter of 2026
compared with $7 million of income in the second quarter of 2025. The unfavorability was
primarily due to higher net interest expense, partially offset by higher net income from
investments in equity securities.
4 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair
value step-up to inventories for asset acquisitions.

-- 5 of 14 --

- 6 -
The income tax provision for the second quarter of 2026 was $654 million on a pretax
loss of $683 million, resulting in an effective income tax rate of (95.9)%. This effective income
tax rate includes a 108.9 percentage point unfavorable impact of the charge for the acquisition
of Terns, for which no tax benefit was recorded.
GAAP loss per share was $0.54 for the second quarter of 2026 compared with earnings
per share of $1.76 for the second quarter of 2025, largely due to higher charges for business
development transactions, reflecting a $2.31 per share charge in the second quarter of 2026 for
the acquisition of Terns compared with a $0.07 per share charge in the second quarter of 2025
related to a license agreement with Hengrui Pharma.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 81.1% for the second quarter of 2026 compared with
82.2% for the second quarter of 2025. The decrease was primarily due to higher inventory write-
downs.
Non-GAAP SG&A expenses were $2.9 billion in the second quarter of 2026, an increase
of 10% compared with the second quarter of 2025. The increase was primarily due to higher
administrative costs (including investments in IT), as well as higher promotional costs in support
of product launches.
Non-GAAP R&D expenses were $9.7 billion in the second quarter of 2026 compared
with $4.0 billion in the second quarter of 2025. The increase was largely due to a $5.7 billion
charge for the acquisition of Terns and higher clinical development spending, partially offset by
a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone. R&D
expenses in the second quarter of 2025 include a $200 million charge for an upfront payment
related to a license agreement with Hengrui Pharma.
Non-GAAP other (income) expense, net, was $290 million of expense in the second
quarter of 2026 compared with $54 million of expense in the second quarter of 2025. The
unfavorability was primarily due to higher net interest expense.
The non-GAAP income tax provision for the second quarter of 2026 was $882 million on
pretax income of $550 million, resulting in a non-GAAP effective income tax rate of 160.3%.
This effective income tax rate includes a 146.2 percentage point unfavorable impact of the
charge for the acquisition of Terns, for which no tax benefit was recorded.
Non-GAAP loss per share was $0.13 for the second quarter of 2026 compared with
earnings per share of $2.13 for the second quarter of 2025, largely due to higher charges for
business development transactions, reflecting a $2.31 per share charge in the second quarter of
2026 for the acquisition of Terns compared with a $0.07 per share charge in the second quarter
of 2025 related to a license agreement with Hengrui Pharma.

-- 6 of 14 --

- 7 -
A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the
table that follows.
Pipeline and Portfolio Highlights
In the second quarter, the Company achieved key regulatory milestones across the
portfolio while continuing to advance its broad and diverse pipeline.
• 	Oncology:
o 	U.S. Food and Drug Administration (FDA) approved KEYTRUDA and
KEYTRUDA QLEX, each with WELIREG, for the adjuvant treatment of certain
patients with clear cell renal cell carcinoma (ccRCC), based on Phase 3
LITESPARK-022 trial.
§ 	Approvals represent first approved combination of a PD-1 and hypoxia-
inducible factor-2 alpha inhibitor for these patients.
o 	In July, FDA approved expanded use of KEYTRUDA and KEYTRUDA QLEX,
each with Padcev, as treatment before and after surgery for adult patients with
muscle-invasive bladder cancer (MIBC), including cisplatin eligible patients
based on Phase 3 KEYNOTE-B15 trial; the expansion builds upon prior approval
of this regimen for cisplatin ineligible patients based on Phase 3 KEYNOTE-905
trial.
o 	FDA approved KEYTRUDA and KEYTRUDA QLEX, each with Trodelvy, for the
first-line treatment of PD-L1 positive (Combined Positive Score [CPS] ≥10)
advanced TNBC, based on Phase 3 KEYNOTE-D19/ASCENT-04 trial.
o 	FDA granted Breakthrough Therapy designation (BTD) for calderasib (MK-1084),
an investigational oral specific KRAS G12C inhibitor, in combination with
KEYTRUDA, for the first-line treatment of patients with advanced or metastatic
5 Includes the estimated income tax impacts on the reconciling items based on applying the statutory rate of the originating territory
of the non-GAAP adjustments for all periods presented. Amount in the second quarter of 2025 also includes a $146 million benefit
primarily resulting from favorable audit reserve adjustments.
Second Quarter
$ in millions, except EPS amounts 	2026 	2025
EPS
GAAP EPS 	$(0.54) 	$1.76
Difference 	0.41 	0.37
Non-GAAP EPS that excludes items listed below3 	$(0.13) 	$2.13
Net (Loss) Income
GAAP net (loss) income2 	$(1,335) 	$4,427
Difference 	1,005 	939
Non-GAAP net (loss) income that excludes items listed below2,3 	$(330) 	$5,366
Excluded Items:
Acquisition- and divestiture-related costs4 	$1,090 	$594
Restructuring costs 	334 	779
Income from investments in equity securities 	(191) 	(61)
Increase to net loss / decrease to net income before taxes 	1,233 	1,312
Estimated income tax benefit5 	(228) 	(373)
Increase to net loss / decrease to net income 	$1,005 	$939

-- 7 of 14 --

- 8 -
non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and expressing
PD-L1 (tumor proportion score [TPS] ≥1%).
o 	Announced that Phase 3 TroFuse-005 trial evaluating sac-TMT, an
investigational anti-TROP2 antibody-drug conjugate (ADC) being developed in
collaboration with Kelun-Biotech, met its primary endpoints of overall survival
(OS) and progression-free survival (PFS) in patients with advanced or recurrent
endometrial cancer who have progressed after platinum-based chemotherapy
and anti-PD-1/L1 immunotherapy.
§ 	First Phase 3 results from the Company’s broad sac-TMT clinical
development program, which includes 17 ongoing global Phase 3 trials
across multiple tumor types.
o 	At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, new
research was presented across over 25 types of cancer, reinforcing long-term
impact of KEYTRUDA and momentum in the Company’s rapidly advancing
oncology pipeline, including:
§ 	Five-year follow-up data from Phase 2b KEYNOTE-942 trial, in
collaboration with Moderna, underscoring continued potential of
intismeran autogene (mRNA-4157/V940) in combination with KEYTRUDA
for patients with stage III/IV melanoma following complete resection.
§ 	Data from Phase 3 OptiTROP-Lung05 trial, led by Kelun-Biotech,
evaluating sac-TMT plus KEYTRUDA in China, adding to ongoing
research of novel treatment approaches for patients with NSCLC.
§ 	Results from final analysis of KEYNOTE-522 evaluating KEYTRUDA in
combination with chemotherapy, reporting a continued survival benefit for
patients with high-risk early-stage TNBC.
• 	Vaccines and Infectious Diseases:
o 	In July, presented new data for daily and weekly options across HIV treatment
and prevention pipeline at 26th International AIDS Conference (AIDS 2026).
Hosted HIV investor event to highlight these data.
§ 	In collaboration with Gilead, presented first Phase 3 results for
islatravir/lenacapavir (ISL/LEN), an investigational oral once-weekly
single-tablet HIV treatment regimen, which maintained virological
suppression in adults with HIV who switched antiretroviral therapy.
ISL/LEN has the potential to be the first approved oral, once-weekly HIV
treatment.
§ 	Presented first results from a Phase 2b study evaluating switch to
investigational once-weekly oral islatravir and ulonivirine (ISL/ULO) in
adults with virologically suppressed HIV-1.
o 	Received regulatory approvals in Japan and China for ENFLONSIA for the
prevention of RSV lower respiratory tract disease in newborns and infants who
are born during or entering their first RSV season.

-- 8 of 14 --

- 9 -
• 	Cardiometabolic and Respiratory:
o 	In July, FDA approved LIPFENDRA (enlicitide), the first and only once-daily oral
PCSK9 inhibitor, as an adjunct to diet and exercise, to reduce LDL-C in adults
with hypercholesterolemia, based on two Phase 3 trials from the CORALreef
clinical program: CORALreef Lipids and CORALreef HeFH.
§ 	At week 24, LIPFENDRA significantly reduced LDL-C by a placebo-
adjusted 56% and 59%, respectively.
• 	Immunology:
o 	Announced positive topline results from Phase 3 ATLAS-UC induction-only study
(Study 2) evaluating tulisokibart (MK-7240), an investigational humanized
monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in
patients with moderately to severely active ulcerative colitis (UC).
o 	Initial topline results from primary analyses of two Phase 2 studies evaluating
tulisokibart:
§ 	In hidradenitis suppurativa (HS), the study met its primary and key
secondary endpoints. Full results will be shared at an upcoming medical
meeting.
§ 	In systemic sclerosis-associated interstitial lung disease (SSc-ILD), the
study did not meet its primary endpoint and will be discontinued. No new
safety concerns were identified.
• 	Business Development:
o 	Completed acquisition of Terns for $6.8 billion.
§ 	Added MK-4208, a novel investigational oral allosteric BCR::ABL1
tyrosine kinase inhibitor recently granted BTD by the FDA for the
treatment of certain adults with Philadelphia chromosome-positive chronic
myeloid leukemia.

-- 9 of 14 --

- 10 -
Notable recent news releases on the Company’s pipeline and portfolio are provided in
the table that follows. Visit the News Releases section of the Company’s website to read the
releases.*
Oncology
FDA Approved KEYTRUDA and KEYTRUDA QLEX, Each With WELIREG, for Adjuvant
Treatment of Certain Patients With ccRCC; Based on Results From Phase 3 LITESPARK-
022 Trial
FDA Approved KEYTRUDA and KEYTRUDA QLEX, Each With Padcev, as Treatment
Before and After Surgery for Adults With MIBC; Based on Results From Phase 3
KEYNOTE-B15 Trial, Combined With Previous Approvals Based on Phase 3 KEYNOTE-
905 Trial
FDA Approved KEYTRUDA and KEYTRUDA QLEX, Each With Trodelvy, as First-Line
Treatment of PD-L1+ Advanced TNBC; Based on Results From Phase 3 KEYNOTE-
D19/ASCENT-04 Trial
European Commission Approved KEYTRUDA Plus Padcev as First PD-1 Inhibitor Plus
ADC Regimen for Adults With Cisplatin-Ineligible Resectable MIBC; Based on Results
From Phase 3 KEYNOTE-905 Trial
FDA Granted BTD for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for
Certain Patients With Newly Diagnosed Metastatic KRAS G12C-Mutant NSCLC
The Company Announced TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints
of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer
The Company and Moderna Presented 5-Year Data for Intismeran Autogene in
Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following
Complete Resection at ASCO 2026
KEYTRUDA as Monotherapy Significantly Improved PFS in Certain Patients With
Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient Tumors
Compared to Chemotherapy; Results From Phase 3 KEYNOTE-C93 Trial
The Company Highlighted New Long-Term Data and Advancements Across Broad
Oncology Portfolio and Pipeline Research at ASCO 2026
The Company Completed Acquisition of Terns
Vaccines and
Infectious Diseases
The Company, in Collaboration With Gilead, Announced That the Once-Weekly
Investigational Oral HIV Treatment Regimen of Islatravir and Lenacapavir (ISL/LEN)
Maintained Virological Suppression in People With HIV Who Switched Antiretroviral
Therapy
The Company Presented New Data on Daily, Weekly and Monthly Options Across its HIV
Treatment and Prevention Pipeline at AIDS 2026
The Company Announced Initial Access Plans for Alimatravir (MK-8527), Its
Investigational Once-Monthly Oral Pre-Exposure Prophylaxis in Phase 3 Development;
Multi-Faceted Strategy Aims To Enable Rapid, Broad and Sustainable Access to
Alimatravir, if Approved, in Low- And Middle-Income Countries
The Company Announced New Agreement With AIDS Drug Assistance Program Crisis
Task Force To Improve Access and Care for People Living With HIV
FDA Approved an Additional Indication for CAPVAXIVE in Children and Adolescents Aged
2 Through 17 at Increased Risk for Pneumococcal Disease; Based on Results From
Phase 3 STRIDE-13 Trial
Cardiometabolic and
Respiratory
FDA Approved LIPFENDRA, the First and Only Once-Daily Oral PCSK9 Inhibitor To
Reduce LDL-C in Adults With Hypercholesterolemia; Based on Results From CORALreef
Lipids and CORALreef HeFH Trials
Immunology Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC
Induction-only Study in Patients With Moderately to Severely Active UC
Animal Health
The Company’s Animal Health Business Completed Acquisition of TARGAN, Broadening
Its Commercial Poultry Portfolio Through TARGAN’s Innovative High-Speed Biodevice
Technology
*References in the above news release titles have been modified for the purpose of this announcement.

-- 10 of 14 --

- 11 -
Upcoming Investor Event
The Company will hold an Oncology Investor Event to coincide with the European
Society for Medical Oncology Congress 2026 on Monday, Oct. 26, 2026, at 6 p.m. CET / 1 p.m.
EDT, during which senior management will provide an update on the Company’s oncology
strategy and program. The event will take place in Madrid, Spain, and will be accessible via live
audio webcast at this weblink.
Full-Year 2026 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
Full Year 2026
Updated 	Prior
Sales* 	$66.3 billion to $67.3 billion 	$65.8 billion to $67.0 billion
Non-GAAP Gross margin3 	Approximately 81% 	Approximately 82%
Non-GAAP Operating expenses3** 	$42.0 billion to $42.7 billion 	$36.0 billion to $36.8 billion
Non-GAAP Other (income) expense, net3 	Approximately $1.4 billion expense 	Approximately $1.3 billion expense
Non-GAAP Effective income tax rate3 	35.0% to 36.0% 	23.5% to 24.5%
Non-GAAP EPS3*** 	$2.66 to $2.76 	$5.04 to $5.16
Share count (assuming dilution) 	Approximately 2.48 billion 	Approximately 2.48 billion
*The Company does not have any non-GAAP adjustments to sales.
**Includes one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. (Cidara) and $5.7 billion for the acquisition
of Terns. Outlook does not assume any additional significant potential business development transactions.
***Includes one-time charges of $3.62 per share for the acquisition of Cidara and $2.31 per share for the acquisition of Terns.
The Company has not provided a reconciliation of forward-looking non-GAAP gross
margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP
effective income tax rate and non-GAAP EPS to the most directly comparable GAAP measures,
given it cannot predict with reasonable certainty the amounts necessary for such a
reconciliation, including intangible asset impairment charges, legal settlements, and income and
losses from investments in equity securities either owned directly or through ownership interests
in investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the Company’s future GAAP results.
The Company is raising and narrowing the range for its full-year sales outlook and now
anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion, including a positive
impact from foreign exchange of approximately 1% at mid-July 2026 exchange rates.
The Company now expects the full-year non-GAAP effective income tax rate to be
between 35.0% and 36.0%, including the impact of the non-tax deductible one-time charges for
the acquisitions of Cidara and Terns.
The Company now expects full-year 2026 non-GAAP EPS to be between $2.66 and
$2.76, including a positive impact from foreign exchange of approximately $0.15 per share at
mid-July 2026 exchange rates. This range includes one-time charges of $9.0 billion, or $3.62
per share, related to the acquisition of Cidara and $5.7 billion, or $2.31 per share, related to the
acquisition of Terns. This range also includes costs of approximately $0.12 per share to finance
the Terns acquisition and advance MK-4208. The charges related to Terns were not previously

-- 11 of 14 --

- 12 -
included in the outlook. In 2025, non-GAAP EPS of $8.98 was negatively impacted by one-time
charges of $0.20 per share in the aggregate related to certain business development
transactions.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Tuesday, Aug. 4, at 9 a.m. EDT via this weblink. A replay of the webcast, along with the
sales and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available on the Company’s website.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to
save and improve lives around the world. For more than 130 years, we have brought hope to
humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the
forefront of research to deliver innovative health solutions that advance the prevention and
treatment of diseases in people and animals. We foster a diverse and inclusive global workforce
and operate responsibly every day to enable a safe, sustainable and healthy future for all
people and communities.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the Company’s ability to

-- 12 of 14 --

- 13 -
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
Company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described in the forward-looking
statements can be found in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025 and the Company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
ENFLONSIA (clesrovimab-cfor)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
LIPFENDRA (enlicitide)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
OHTUVAYRE (ensifentrine)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###

-- 13 of 14 --

- 14 -
Media Contacts: 	Investor Contacts:
Michael Levey
michael.levey@msd.com
John Cummins
john.cummins2@msd.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 14 of 14 --